$126 Million is the total value of DAFNA Capital Management LLC's 95 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 44.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NXTM | Sell | NXSTAGE MEDICAL INC | $7,729,000 | +30.0% | 356,509 | -10.1% | 6.13% | +19.5% |
| VTAE | Sell | VITAE PHARMACEUTICALS INC | $7,123,000 | +36.5% | 660,188 | -16.2% | 5.64% | +25.4% |
| ABBV | Sell | ABBVIE INC | $4,726,000 | -29.0% | 76,331 | -34.5% | 3.75% | -34.8% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $4,119,000 | +5.5% | 1,847,087 | -1.6% | 3.26% | -3.0% |
| NVAX | Sell | NOVAVAX INC | $3,999,000 | +40.0% | 550,000 | -0.6% | 3.17% | +28.6% |
| GLPG | Sell | GALAPAGOS NVspon adr | $3,526,000 | +28.6% | 63,568 | -3.1% | 2.80% | +18.2% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $3,432,000 | +13.7% | 75,503 | -1.0% | 2.72% | +4.5% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $2,831,000 | +29.5% | 160,869 | -10.5% | 2.24% | +19.0% |
| PODD | Sell | INSULET CORP | $2,787,000 | -20.7% | 92,164 | -13.1% | 2.21% | -27.2% |
| BEAT | Sell | BIOTELEMETRY INC | $1,630,000 | -40.8% | 100,000 | -57.6% | 1.29% | -45.6% |
| RDUS | Sell | RADIUS HEALTH INC | $1,382,000 | +3.2% | 37,600 | -11.7% | 1.10% | -5.2% |
| LDRH | Sell | LDR HLDG CORP | $1,109,000 | -13.5% | 30,000 | -40.4% | 0.88% | -20.5% |
| MASI | Sell | MASIMO CORPORATION | $525,000 | -72.7% | 10,000 | -78.3% | 0.42% | -75.0% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $358,000 | -44.6% | 119,300 | -1.1% | 0.28% | -49.0% |
| ARDX | Sell | ARDELYX INC | $262,000 | -76.0% | 30,000 | -78.6% | 0.21% | -77.9% |
| ABUS | Sell | ARBUTUS BIOPHARMA CORP | $261,000 | -45.2% | 75,000 | -34.9% | 0.21% | -49.6% |
| NMUS | Sell | NEMUS BIOSCIENCE INC | $252,000 | -37.0% | 511,508 | -11.9% | 0.20% | -42.0% |
| ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $203,000 | -71.6% | 24,955 | -71.7% | 0.16% | -73.9% |
| AKBA | Sell | AKEBIA THERAPEUTICS INC | $185,000 | -68.8% | 24,700 | -62.4% | 0.15% | -71.2% |
| CHEK | Sell | CHECK CAP LTD | $123,000 | -49.8% | 88,220 | -1.1% | 0.10% | -54.0% |
| MRNS | Sell | MARINUS PHARMACEUTICALS INC | $115,000 | -96.2% | 90,237 | -84.1% | 0.09% | -96.5% |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $14,000 | -98.1% | 2,499 | -98.6% | 0.01% | -98.3% |
| AKTX | Sell | AKARI THERAPEUTICS PLCsponsored adr | $6,000 | -90.9% | 458 | -90.3% | 0.01% | -91.2% |
| CHEKW | Sell | CHECK CAP LTD*w exp 02/28/202 | $5,000 | -88.1% | 53,488 | -0.4% | 0.00% | -88.9% |
| GLMD | Exit | GALMED PHARMACEUTICALS LTD | $0 | – | -13,488 | -100.0% | -0.06% | – |
| DNAI | Exit | PRONAI THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.06% | – |
| BPMX | Exit | BIOPHARMX CORP | $0 | – | -146,800 | -100.0% | -0.14% | – |
| AFMD | Exit | AFFIMED THERAPEUTICS BV | $0 | – | -46,701 | -100.0% | -0.15% | – |
| STEM | Exit | STEMCELLS INC | $0 | – | -699,563 | -100.0% | -0.16% | – |
| APPY | Exit | VENAXIS INC | $0 | – | -74,350 | -100.0% | -0.17% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -149,642 | -100.0% | -0.36% | – |
| Exit | ENDOLOGIX INCnote 3.250%11/0 added | $0 | – | -500,000 | -100.0% | -0.43% | – | |
| CRDC | Exit | CARDICA INC COM | $0 | – | -140,275 | -100.0% | -0.43% | – |
| Exit | IRONWOOD PHARMAnote 2.25% 15-jun-2022 144a sr unsecured conv | $0 | – | -600,000 | -100.0% | -0.47% | – | |
| EDGE | Exit | EDGE THERAPEUTICS INC | $0 | – | -69,177 | -100.0% | -0.55% | – |
| TBRA | Exit | TOBIRA THERAPEUTICS INC | $0 | – | -81,402 | -100.0% | -0.58% | – |
| CDNA | Exit | CAREDX INC | $0 | – | -136,047 | -100.0% | -0.58% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -47,500 | -100.0% | -0.59% | – |
| AAVL | Exit | AVALANCHE BIOTECHNOLOGIES IN | $0 | – | -140,600 | -100.0% | -0.63% | – |
| DSCO | Exit | DISCOVERY LABORATORIES INC N COM PAR | $0 | – | -533,358 | -100.0% | -0.77% | – |
| MNOV | Exit | MEDICINOVA INC | $0 | – | -125,000 | -100.0% | -0.79% | – |
| LPCN | Exit | LIPOCINE INC | $0 | – | -95,731 | -100.0% | -0.84% | – |
| CYAD | Exit | CELYADadr | $0 | – | -30,000 | -100.0% | -1.14% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.